2024-10-18 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops, manufactures, and markets a wide range of prescription medicines.

**1. Performance Comparison with S&P 500:**

* **Cumulative return (LLY):** 883.11%
* **Cumulative return (VOO):** 136.93%
* **Return difference:** 746.18%
* **Relative divergence:** 92.59% (This means the current outperformance of LLY compared to VOO sits at the 92.59 percentile of its historical range)

**2. Recent Price Action:**

* **Closing Price:** 916.42
* **5-day Moving Average:** 919.98
* **20-day Moving Average:** 907.4
* **60-day Moving Average:** 897.6

The stock is currently trading above its short-term and long-term moving averages, indicating potential upward momentum.

**3. Technical Indicators:**

* **RSI:** 52.55 (Neutral)
* **PPO:** 0.27 (Slightly bullish)
* **Delta_Previous_Relative_Divergence:** -0.18 (Indicates a recent slight decline in relative performance)
* **Expected Return:** 35.33% (Projected 5-year expected return compared to the S&P 500, VOO)

The RSI and PPO indicators suggest a neutral to slightly bullish sentiment. The negative delta in the relative divergence indicates a slight short-term correction, but the projected return remains positive.

**4. Recent Earnings and Outlook:**

| Date       | EPS   | Revenue  |
|------------|-------|----------|
| 2024-08-08 | 3.29  | 11.30 B$ |
| 2024-04-30 | 2.49  | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96  | 8.31 B$ |
| 2024-08-08 | 1.96  | 8.31 B$ |

The most recent earnings report for the quarter ending August 8, 2024, showed EPS of 3.29, exceeding analysts' expectations. Revenue also beat expectations at 11.30 billion dollars. This strong performance reflects the company's continued growth and market dominance.

**5. News and Recent Issues:**

**Recent Market Outlook:** Eli Lilly is a leading player in the pharmaceutical industry, benefiting from strong demand for its products, particularly in the diabetes and oncology segments. Recent FDA approvals of new drug candidates and the company's strong financial performance continue to support a positive outlook. 

**Analyst Opinions:** Analyst consensus for LLY remains bullish, with a majority recommending a "buy" or "strong buy." They cite factors such as strong earnings growth, a robust pipeline of new drugs, and the company's dominant market position.

**Performance Highlights:** Eli Lilly has been a consistent performer, delivering strong returns for investors. The company's stock price has been steadily climbing over the years, driven by its successful drug development and expansion into new markets.

**6. Overall Analysis:**

Eli Lilly and Co presents a compelling investment opportunity, with a strong track record of growth and innovation. The company's leading market position, robust pipeline of new drugs, and strong recent earnings performance suggest continued growth and outperformance compared to the broader market. While a slight short-term correction is possible, the long-term outlook remains positive with a projected 5-year expected return exceeding the S&P 500.

**7. Conclusion:**

Based on the analysis of its performance, financial health, and market positioning, Eli Lilly and Co (LLY) remains a solid investment choice for long-term investors seeking exposure to the pharmaceutical sector. 
